None listed
Conditions
Brief summary
Our study is Randomized Controlled trial and it aims to collect evidence regarding superiority of levetiracetam over phenytoin as a second line drug used in management of status epilepticus in children. This will help in development of future guidelines and amendments in existing protocols regarding management of status epilepticus .Outcome will be measured as presence or absence of seizures at 15 minutes and 30 minutes time points after completion of infusion of each drug.
Interventions
Participants assigned to levetiracetam group will receive 40 mg/kg intravenous levetiracetam infusion over 5 min (maximum 2.5g, diluted with 0·9% sodium chloride) and emergency doctor attending that patient will document the prescribed infusion in patient file and monitor the clinical signs for cessation of seizures.
Sponsors
Dr Hina Parvaiz- Medical Teaching Institute Lady Reading Hospital Peshawar
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)
Eligibility
Sex/Gender
All
Age
2 Months to 15 Years
Healthy volunteers
No
Inclusion criteria
: children between age of 2 months to 15 years presenting with convulsive status epilepticus and having received two doses of benzodiazepines as first line anticonvulsant.
Exclusion criteria
Children who received second line anticonvulsants already or become seizure free after first two doses of benzodiazepines will be excluded. Children with chronic liver disease or kidney disease or any metabolic diseases, causing derangements in blood glucose levels or electrolytes derangements. Children with head trauma will also be excluded. Children with any history of allergy to phenytoin or levetiracetam will also be excluded
Outcome results
None listed